EFFICACY AND SAFETY OF GLOFITAMAB IN RELAPSED/REFRACTORY B-CELL NON HODGKIN LYMPHOMA: RESULTS FROM THE RETROSPECTIVE OBSERVATIONAL GIMEMA-FIL IMM0123 STUDY (SIE 2026) - Oct 6, 2026 - Abstract #C005; Pres time: Sep 21, 2026; 11:50 AM - 01:20 PM; Location: HALL 1; "In this real-world compassionate-use setting, Glofitamab demonstrated a meaningful clinical activity and a manageable safety profile in heavily pretreated patients with R/R B cell NHL with results consistent with findings from other real-world studies. Among patients who achieved CR, sustained OS and PFS at 2 years of follow-up further support these promising results, showing Glofitamab as an effective salvage treatment option for R/R NHL patients."
Retrospective data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin's Lymphoma
|
|
A. Guidetti1; A. Talone2; B. Casadei3; P. R. Scalzulli4; L. Nassi5; M. C. Tisi6; V. Bolis7; E. Ravano8; F. D'Alò9; F. Piazza10; E. Lucchini11; E. Pennese12; F. Ballerini13; A. Castellino14; G. Gini15; A. Di Rocco16; M. Musso17; M. Frascione18; A. M. Carella19; M. Iodice2; A. Piciocchi2; P. L. Zinzani20; P. Corradini1
|